Review of 2025 approved small-molecule drugs by China NMPA: A new milestone
Authors:
- Yuegao HuYHYuegao Hu
- Fengming HeFHFengming He
- Chunyan HeCHChunyan He
- Cuiting CaoCCCuiting Cao
- Nanshan ZhongNZNanshan Zhong
- Zifeng YangZYZifeng Yang
- Yingjun LiYLYingjun Li
Open Access
- 17 October 2026
- journal article
- review article
- Published by Elsevier in Acta Pharmaceutica Sinica B
Abstract
No abstract availableFunding Information
- Guangzhou Medical University
This publication has 273 references indexed in Scilit:
- Efficacy and Safety of Ivarmacitinib, a Selective JAK1 Inhibitor, in Patients With Active Ankylosing Spondylitis: Results From an Adaptive Seamless Phase 2/3 TrialArthritis & Rheumatology, 2025
- Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor–Positive and ERBB2-Negative Advanced Breast Cancer After Endocrine TherapyJAMA Oncology, 2025
- An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trialCancer Communications, 2025
- Efficacy, safety, and survival findings after long‐term follow‐up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosisAmerican Journal of Hematology, 2024
- Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single‐arm, open‐label, phase 2, multicenter studyAmerican Journal of Hematology, 2023
- Safety and efficacy of jaktinib (a novelJAKinhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: Asingle‐arm,open‐label, phase 2, multicenter studyAmerican Journal of Hematology, 2023
- A phase II study on Mefatinib as first‐line treatment of patients with advanced non‐small‐cell lung cancer harboring uncommon EGFR mutationsCancer Communications, 2023
- Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor‐naïve patients with myelofibrosis: Results of a phase II trialAmerican Journal of Hematology, 2022
- Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor–Positive, ERBB2-Negative Breast CancerJAMA Oncology, 2020
- Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapyCancer Medicine, 2018